Predict your next investment

Corporation
HEALTHCARE | Biotechnology
adnexustx.com

See what CB Insights has to offer

Total Raised

$68.82M

Investors Count

5

Deal Terms

4

Adnexus Therapeutics Funding, Adnexus Therapeutics Valuation & Adnexus Therapeutics Revenue

7 Fundings

Adnexus Therapeutics's latest funding round was a Acquired for on September 24, 2007.

Adnexus Therapeutics's valuation in February 2007 was $95.68M.

Adnexus Therapeutics's latest post-money valuation is from September 2007.

Sign up for a free trial to see Adnexus Therapeutics's valuations in September 2007, May 2006 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

9/24/2007

Acquired

$99M

1

8/16/2007

Unattributed VC - IV

$99M

0

2/21/2007

Series B

$99M

$95.68M

0

5/8/2006

Unattributed VC - III

$99M

$99M

0

12/15/2004

Series A

$99M

0

Date

9/24/2007

8/16/2007

2/21/2007

5/8/2006

12/15/2004

Round

Acquired

Unattributed VC - IV

Series B

Unattributed VC - III

Series A

Amount

$99M

$99M

$99M

$99M

Investors

Valuation

$99M

$95.68M

$99M

Revenue

Sources

1

0

0

0

0

Adnexus Therapeutics Deal Terms

4 Deal Terms

Adnexus Therapeutics's deal structure is available for 4 funding rounds, including their Acquired from September 24, 2007.

Round

Acquired

Series B

Unattributed VC - III

Series A

Funding Date

$99M

$99M

$99M

$99M

Pre-Money Valuation

$99M

Post-Money Valuation

$99M

$99M

Amount Raised

$99M

$99M

$99M

Shares Authorized

Issuance Price

$99M

Dividend Rate

Liquidation Preferences

$99M

Liquidation Price

Participation

$99M

Conversion Price

Anti Dilution

$99M

General Voting

$99M

$99M

$99M

$99M

Board Voting

$99M

$99M

$99M

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Acquired

$99M

$99M

$99M

$99M

Series B

$99M

$99M

$99M

$99M

Unattributed VC - III

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

$99M

Series A

$99M

$99M

$99M

$99M

Adnexus Therapeutics Investors

5 Investors

Adnexus Therapeutics has 5 investors. Bristol-Myers Squibb invested in Adnexus Therapeutics's Acquired funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

9/24/2007

9/24/2007

1
Acquired

Corporation

New York

00/00/0000

00/00/0000

Flagship Pioneering

Subscribe to see more

Venture Capital

Massachusetts

00/00/0000

00/00/0000

Atlas Venture

Subscribe to see more

Venture Capital

Massachusetts

00/00/0000

00/00/0000

Polaris Partners

Subscribe to see more

Venture Capital

Massachusetts

00/00/0000

00/00/0000

Venrock

Subscribe to see more

Venture Capital

California

First funding

9/24/2007

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Last Funding

9/24/2007

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Investor

Flagship Pioneering

Atlas Venture

Polaris Partners

Venrock

Rounds

1
Acquired

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Board Seats

Type

Corporation

Venture Capital

Venture Capital

Venture Capital

Venture Capital

Location

New York

Massachusetts

Massachusetts

Massachusetts

California

Adnexus Therapeutics Acquisitions

1 Acquisition

Adnexus Therapeutics acquired 1 company. Their latest acquisition was Phylos on December 05, 2003.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/5/2003

Other Venture Capital

$99M

$25.1M

Acquired

Date

12/5/2003

Investment Stage

Other Venture Capital

Companies

Valuation

$99M

Total Funding

$25.1M

Note

Acquired

Sources

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.